Market Overview

UPDATE: Piper Jaffray Upgrading Acorda Therapeutics


Piper Jaffray is upgrading shares of Acorda Therapeutics (NASDAQ: ACOR) to Neutral from Underweight, and it has a $30 price target on shares.

In a note to investors, Piper Jaffray writes, "With the European Medicine Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) reversing itself, now recommending conditional marketing authorization for Fampyra (the ex-U.S. trade name for Ampyra), we are upgrading Acorda to a Neutral from Underweight. The reversal was a surprise to us given that the CHMP initially cited a "small effect on walking speed" as a basis for its rejection. We are expecting approval in 3Q11, and with the inclusion of royalties from partner Biogen Idec, we are raising our price target to $30 from $21. That said, we remain cautious regarding the U.S. sales trajectory for Ampyra, and would expect similar dynamics in the EU."

Shares of ACOR gained $3.67 on Friday to close at $30.38, a gain of almost 14%.

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (ACOR + CHMP)

View Comments and Join the Discussion!

Latest Ratings

SLABSummit Insights GroupDowngrades
WSBCStephens & Co.Maintains39.0
MRCYCanaccord GenuityMaintains85.0
CRCanaccord GenuityMaintains88.0
EBAYCanaccord GenuityMaintains38.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at